The full programme for the combined Barcelona Vaccine Forum 2010 and Active Immunotherapeutics Forum 2010 is posted below. If you would like to suggest any additional topics you would like to see addressed, please contact David McCall at david@phacilitate.co.uk.
|
Day 1 - Monday, June 21st, 2010
|
|
Barcelona Vaccine Forum
|
Active Immunotherapeutcs Forum
|
|
|
Morning plenary session »
|
|
How did we do and what have we learnt? Multiple stakeholder 'debrief' on preparations for, and the response to, the 2009/10 H1N1 influenza pandemic
|
Learning strategic lessons from the first AI product launch(es)
• How do development and commercialisation pathways need to differ from traditional cytotoxic drug development?
|
Followed by your choice of four highly interactive parallel sessions:
|
|
Focus session 1 »
How have seasonal and pandemic influenza vaccine markets - and the regulatory environment - evolved over the past year, and how must the industry respond to ensure future success?
|
Workshop »
Delivering biotech corporate development and fund-raising strategies to beat the economic downturn
After morning coffee you may wish to join the Active Immunotherapeutics Workshop, which includes vaccine examples
|
Focus session 1 »
Early application of statistical methods, flexible approaches and adaptive design in order to better inform pivotal and phase III studies in AI
|
Workshop »
Optimising the time, money and effort spent on preclinical development: Pushing for early translation into human trials
|
Followed by your choice of two parallel sessions:
|
|
Afternoon plenary session »
Getting ready for the next influenza pandemic: How are recent experiences informing ongoing preparedness strategies?
|
Afternoon plenary session »
What is big pharma’s current view of the viability and promise of the AI business model?
|
|
|
Day 2 - Tuesday, June 22nd, 2010
|
| Barcelona Vaccine Forum |
Active Immunotherapeutcs Forum |
Your choice of two parallel sessions:
|
|
Morning plenary session »
How are innovative partnering models and funding opportunities enabling vaccine market development on a global scale?
|
Morning plenary session »
Preparing for registration: Generating high quality mid- to late-stage efficacy data to guarantee a robust registration package
|
Followed by your choice of four highly interactive parallel sessions:
|
|
Focus session »
Where next for novel cell culture and other bioprocessing technologies in the wake of the H1N1 pandemic?
|
Workshop »
What will be the successful business model for capitalising on R&D and commercial opportunities in the 'BRIC nations'? (Brazil, Russia, India, China)
|
Focus session »
Identifying, validating and applying predictive biomarkers to improve targeting, decision-making and - ultimately - success in cancer vaccines
|
Workshop »
Chronic infectious diseases: How is AI driving innovation and progress in this sector, and what translational opportunities are there for other disease areas?
|
Followed by your choice of two parallel sessions:
|
|
Afternoon plenary session »
HIV vaccines: Dissecting recent clinical data to deliver pathways forward
|
Afternoon plenary session »
Planning your combination strategies: Synergistic effects or completely the contrary?
- Making the right business decisions about how and when to consider combinations and with what
|
|
|
Day 3 - Wednesday, June 23rd, 2010
|
| Barcelona Vaccine Forum |
Active Immunotherapeutcs Forum |
your choice of two parallel sessions:
|
|
Morning plenary session »
Assessing the value and feasibility of emerging vaccine targets and markets in an evolving healthcare environment
• What lessons can be learned from pneumococcal and HPV vaccine success stories to inform both R&D and market development strategies for potential future blockbusters?
|
Morninglenary session »
How do you properly modulate the immune system? Tackling its multiple components and mechanisms of action to overcome the biological challenges
|
Followed by your choice of four highly interactive parallel sessions:
|
|
Focus session »
Are novel adjuvants realising their potential in influenza and other vaccine target areas?
- Addressing remaining R&D and regulatory challenges
|
Workshop »
European regulatory update: Clarifying recent and novel guidelines, and delivering the keys to successful and efficient navigation
|
Focus session »
Methodologies to measure the potency of AI candidates and remove this major obstacle to the progression of products in pivotal trials
|
Workshop »
Active immunosuppression: How might progress in the autoimmune and allergy fields inform AI candidates for cancer and infectious diseases?
|
